Market advancements are driven by rising incidences of neuroendocrine tumors, improved diagnostics, and targeted therapies. Key players like Novartis AG and Pfizer Inc. are investing in innovative ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Perspective Therapeutics, Inc. ("Perspective” or the "Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced ...

Scientists at the University of Michigan Rogel Cancer Center have found a promising new way to fight one of the most ...

Radiopharmaceutical publicly funded in some provinces has fewer side effects than chemotherapy and can increase survival by ...

The study, published in the Journal of Clinical Investigation, reveals that pyrvinium pamoate—a drug approved in the 1950s to ...

A “determined and courageous” event rider who died aged 30 has left a legacy of hope. Miranda Filmer died in 2022, five years ...

A Tulsa woman now gets her cancer treatments five minutes from home, instead of in Oklahoma City, because of the OU Health Stephenson Cancer Center's new partnership with Hillcrest.

A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, ...

A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers ...